157 related articles for article (PubMed ID: 36799155)
1. Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring.
Wiken TH; Høivik ML; Buer L; Warren DJ; Bolstad N; Moum BA; Anisdahl K; Småstuen MC; Medhus AW
Scand J Gastroenterol; 2023; 58(8):863-873. PubMed ID: 36799155
[TBL] [Abstract][Full Text] [Related]
2. Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease.
Lamichhane N; Melas N; Bergqvist V; ; Ekholm NP; Olén O; Ludvigsson JF; Hjortswang H; Marsal J; Eriksson C; Halfvarson J
Dig Dis Sci; 2024 Jun; 69(6):2175-2183. PubMed ID: 38637457
[TBL] [Abstract][Full Text] [Related]
3. Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases.
Volkers A; Straatmijer T; Duijvestein M; Sales A; Levran A; van Schaik F; Maljaars J; Gecse K; Ponsioen C; Grootjans J; Hanzel J; Tack G; Jansen J; Hoentjen F; de Boer N; van der Marel S; Dijkstra G; Oldenburg B; Löwenberg M; van der Meulen A; D Haens G;
Aliment Pharmacol Ther; 2022 Sep; 56(6):1044-1054. PubMed ID: 35869807
[TBL] [Abstract][Full Text] [Related]
4. Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease.
Pintar Š; Hanžel J; Drobne D; Koželj M; Kurent T; Smrekar N; Novak G
Medicina (Kaunas); 2024 Feb; 60(2):. PubMed ID: 38399583
[No Abstract] [Full Text] [Related]
5. Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.
Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Ferrante M; Jordi Guardiola ; Jahnsen J; Louis E; Lukáš M; Reinisch W; Roblin X; Smith PJ; Kwon T; Kim J; Yoon S; Kim DH; Atreya R
BMC Gastroenterol; 2024 Mar; 24(1):121. PubMed ID: 38539103
[TBL] [Abstract][Full Text] [Related]
6. Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: impact on trough levels, day hospital visits, and medical expenses.
Harno-Tasihin J; Siregar L; Paajanen M; Arkkila P; Punkkinen J
Scand J Gastroenterol; 2024 Mar; 59(3):280-287. PubMed ID: 38006219
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
Smith PJ; Critchley L; Storey D; Gregg B; Stenson J; Kneebone A; Rimmer T; Burke S; Hussain S; Yi Teoh W; Vazeille S; Serna S; Steel A; Derbyshire E; Collins P; Dibb M; Flanagan P; Probert C; Verma AM; Subramanian S
J Crohns Colitis; 2022 Sep; 16(9):1436-1446. PubMed ID: 35390141
[TBL] [Abstract][Full Text] [Related]
8. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A
J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
[TBL] [Abstract][Full Text] [Related]
9. Switching Vedolizumab from IV to SC Injection in Inflammatory Bowel Disease Patients with Active Disease: Real-World Experience from a German IBD Cohort.
Kubesch A; Kruse N; Jungheim F; Balaban Ü; Stratmann K; Sprinzl K; Dienethal A; Krause T; Zeuzem S; Blumenstein I
J Clin Med; 2023 Dec; 12(24):. PubMed ID: 38137726
[TBL] [Abstract][Full Text] [Related]
10. Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease.
Bergqvist V; Holmgren J; Klintman D; Marsal J
Aliment Pharmacol Ther; 2022 Jun; 55(11):1389-1401. PubMed ID: 35470449
[TBL] [Abstract][Full Text] [Related]
11. Transitioning from Intravenous to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease [TRAVELESS].
Ventress E; Young D; Rahmany S; Harris C; Bettey M; Smith T; Moyses H; Lech M; Gwiggner M; Felwick R; Cummings JRF
J Crohns Colitis; 2022 Jul; 16(6):911-921. PubMed ID: 34935945
[TBL] [Abstract][Full Text] [Related]
12. Benefit of measuring vedolizumab concentrations in inflammatory bowel disease patients in a real-world setting.
Kolehmainen S; Ylisaukko-Oja T; Jokelainen J; Koivusalo M; Jokiranta TS; Sipponen T
Scand J Gastroenterol; 2021 Aug; 56(8):906-913. PubMed ID: 34154506
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
[TBL] [Abstract][Full Text] [Related]
14. Vedolizumab subcutaneous formulation maintenance therapy for patients with IBD: a systematic review and meta-analysis.
Hu Q; Tang XZ; Liu F; Liu DW; Cao B
Therap Adv Gastroenterol; 2023; 16():17562848231166227. PubMed ID: 37124368
[TBL] [Abstract][Full Text] [Related]
15. Vedolizumab Is Safe and Efficacious for the Treatment of Pediatric-Onset Inflammatory Bowel Disease Patients Who Fail a Primary Biologic Agent.
Choi S; Kim ES; Kwon Y; Kim MJ; Choe YH; Choe BH; Kang B
J Korean Med Sci; 2022 Sep; 37(37):e282. PubMed ID: 36163478
[TBL] [Abstract][Full Text] [Related]
16. Drug levels of VEDOLIZUMAB in patients with pediatric-onset inflammatory bowel disease in a real-life setting.
Hemming-Harlo M; Merras-Salmio L; Nikkonen A; Kolho KL
Eur J Pediatr; 2024 Jan; 183(1):313-322. PubMed ID: 37878072
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission.
Parisio L; Settanni CR; Varca S; Laterza L; Lopetuso LR; Napolitano D; Schiavoni E; Turchini L; Fanali C; Alfieri N; Pizzoferrato M; Papa A; Pafundi PC; Armuzzi A; Gasbarrini A; Pugliese D; Scaldaferri F
J Gastrointestin Liver Dis; 2023 Dec; 32(4):452-459. PubMed ID: 38147610
[TBL] [Abstract][Full Text] [Related]
18. Entyvio lengthen dose-interval study: lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel disease.
Chan W; Lynch N; Bampton P; Chang J; Chung A; Florin T; Hetzel DJ; Jakobovits S; Moore G; Pavli P; Radford-Smith G; Thin L; Baraty B; Haifer C; Yau Y; Leong RWL
Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):735-740. PubMed ID: 29727386
[TBL] [Abstract][Full Text] [Related]
19. Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort.
Buer LCT; Moum BA; Cvancarova M; Warren DJ; Bolstad N; Medhus AW; Høivik ML
Scand J Gastroenterol; 2019 Jan; 54(1):41-48. PubMed ID: 30650312
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study.
Wiken TH; Høivik ML; Anisdahl K; Buer L; Warren DJ; Bolstad N; Hagen M; Moum BA; Medhus AW
Crohns Colitis 360; 2024 Jan; 6(1):otae013. PubMed ID: 38544907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]